SCHEMBL18367285

SCHEMBL18367285

COC(=O)CCC(=O)c1ccc(Br)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.50
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.48
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC6A4 P31645 1/20 0.42
ACKR3 P25106 2/20 0.42
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7887281 0.88 DGAT1 (0.53) DGAT1HSD17B10KDM4ETP53HPGD
SCHEMBL13451235 0.85 DGAT1 (0.47) DGAT1HPGDKMT2AMEN1ALDH1A1
SCHEMBL20095552 0.85 DGAT1 (0.47) DGAT1HSD17B10KDM4ETP53HPGD
SCHEMBL4124567 0.82 HSD17B10 (0.49) HSD17B10KDM4ETP53HPGDKMT2A
SCHEMBL11257223 0.82 GAA (0.44) HSD17B10KDM4ETP53KMT2AALDH1A1
SCHEMBL14055194 0.81 TMEM97 (0.53) DGAT1KDM4EHPGDKMT2AL3MBTL1
SCHEMBL11900526 0.81 DGAT1 (0.56) DGAT1HSD17B10KDM4EHPGDKMT2A
SCHEMBL1568667 0.78 DGAT1 (0.49) DGAT1KDM4EHPGDKMT2AMEN1
SCHEMBL3054837 0.78 DGAT1 (0.56) DGAT1KMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL17506959 0.78 DGAT1 (0.56) DGAT1KMT2AALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 US disclosed
US-12139482-B2 Bicyclic pyridone lactams and methods of use thereof GENENTECH, INC. (US) 2024-11-12 US disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 EP disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 CN disclosed
EP-4095138-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2022-11-30 EP disclosed
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-11-03 US disclosed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 EP disclosed
EP-3555093-B1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2022-09-21 EP disclosed
CN-110072863-B RIP1 kinase inhibitors and methods of use 豪夫迈·罗氏有限公司 2022-08-30 CN disclosed
CN-109843886-B Bicyclic pyridone lactams and methods of use thereof 豪夫迈·罗氏有限公司 2022-04-19 CN disclosed
WO-2018109097-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-06-21 WO disclosed
EP-3317269-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF H. Hoffnabb-La Roche Ag (CH) 2018-05-09 EP disclosed
WO-2018073193-A1 BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-04-26 WO disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 WO disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 DGAT1 4250/4885HSD17B10 942/4885KDM4E 3546/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 DGAT1 4250/4885HSD17B10 942/4885KDM4E 3546/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 DGAT1 4250/4885HSD17B10 942/4885KDM4E 3546/4885
US-12139482-B2 Bicyclic pyridone lactams and methods of use thereof CYP3A5, C5, PDXK DGAT1 4853/4885HSD17B10 1649/4885KDM4E 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.